Transcode Therapeutics, INC. (RNAZ) — DEFA14A Filings
All DEFA14A filings from Transcode Therapeutics, INC.. Browse 6 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (6)
- DEFA14A Filing — Apr 7, 2026
-
TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split
— Apr 16, 2025 Risk: medium
TransCode Therapeutics, Inc. is holding a special meeting on April 21, 2025, to vote on a proposal to authorize a reverse stock split. The company is urging sha -
TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split
— Nov 13, 2024 Risk: medium
TransCode Therapeutics, Inc. is holding a Special Meeting on November 22, 2024, where shareholders will vote on a proposal to authorize the Board of Directors t -
TransCode Therapeutics Regains Nasdaq Listing Compliance
— Jun 10, 2024 Risk: medium
TransCode Therapeutics, Inc. announced on June 10, 2024, that Nasdaq has determined the company has regained compliance with its continued listing requirements. -
TransCode Therapeutics Seeks Shareholder Vote on Reverse Stock Split
— May 13, 2024 Risk: medium
TransCode Therapeutics, Inc. filed a DEFA14A proxy statement on May 13, 2024, to solicit votes on a proposed reverse stock split. The company, headquartered in -
TransCode Therapeutics Details 2023 Progress, 2024 Objectives in Shareholder Letter
— Jan 4, 2024
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) published an open letter to shareholders on January 4, 2024, detailing its progress in 2023 and objectives for 2024.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX